A reoccurrence of 2015 spray of losses may just be imminent for Neimeth International Pharmaceuticals Plc if its newly appointed Chief Executive Officer (CEO), Pharm. Matthew Azoji, fails to tackle the company’s revenue challenges on his assumption of office come Feb. 1.
Azoji holds a first-cla
```
Members Only
Login or create an account to continue
This article is available to registered BusinessDay readers. Please login if you already have an account, or create a new account to continue reading.
New to BusinessDay? Register now and start reading.
```
